Slingshot members are tracking this event:
Phase 3 REMARC Trial Data with REVLIMID in DLBCL Maintenance Due Q4 2016
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
Slingshot Insights Explained
Jul 25, 2016
- What Can We Expect from Celgene's Phase 3 REMARC Trial Data for Non-Hodgkin Lymphoma? CELG Execute By: Aug 31, 2016
Related Keywords Phase 3 Data, Remarc Trial, Revlimid, Lenalidomide, Diffuse Large B-cell Lymphoma